Martyn Hiscox
About Martyn Hiscox
Martyn Hiscox is a Principal Scientist at Adaptimmune, where he has worked since 2021. He holds a PhD in Biochemistry from the University of Southampton and has published research on T-cell receptors recognizing human mesothelin.
Work at Adaptimmune
Martyn Hiscox has been serving as a Principal Scientist at Adaptimmune since 2021. In this role, he focuses on advancing research and development in the field of immunotherapy. His expertise contributes to the company's mission of developing T-cell therapies for cancer treatment. Hiscox's work involves collaboration with cross-functional teams to drive scientific innovation and translate research findings into therapeutic applications.
Education and Expertise
Martyn Hiscox earned his Doctor of Philosophy (Ph.D.) in Biochemistry from the University of Southampton, where he studied from 2010 to 2014. Prior to his Ph.D., he completed a Master's Degree in Chemistry at the same institution from 2006 to 2010. His educational background provides a strong foundation in biochemical research, which supports his current role in the development of T-cell therapies.
Published Research
In 2024, Martyn Hiscox published research in PLOS ONE, focusing on human leukocyte antigen-independent T-cell receptors that recognize human mesothelin. This work contributes to the understanding of T-cell receptor biology and its implications for cancer immunotherapy. His research findings aim to enhance the effectiveness of T-cell therapies by exploring novel receptor mechanisms.
Presentations and Conferences
Martyn Hiscox presented his research at the ASGCT Annual Meeting in 2021. This conference is a significant event in the field of gene and cell therapy, where scientists share their latest findings and advancements. His participation highlights his engagement with the scientific community and his commitment to disseminating knowledge related to immunotherapy.